PET scan to predict benefit from HER2-targeted breast cancer therapy
Part of Cancer, Skin clinical trials.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have HER2-positive breast cancer based on standard test results (IHC 3+ or specific DNA test patterns)
- Your treatment plan includes at least one anti-HER2 therapy
- You can do the study activities and movement: you must be able to lie still during the scan
- You must be able to undergo MRI (no certain non-removable metal implants or specific contraindicated tattoos)
- You are not pregnant, and you can give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This trial is testing a new type of PET scan (called FAPI) to see if it can help predict how well T-DXd (Enhertu) works on breast cancer that has spread to the brain. Participants will get T-DXd as planned and have the scan before starting treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.